BeOne Medicines Ltd.
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Amgen R&D Financing Liability Amortization by Year
Amgen R&D Financing Liability Amortization (Offset to R&D Expense) ($M) ($M)
BeOne Medicines Amgen R&D Financing Liability Amortization: $101M in FY2025, up 38.1% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Collaborative Arrangements Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Amgen R&D Financing Liability Amortization (Offset to R&D Expense) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 101 | +38.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 73.2 | +32.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 55.3 | -42.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 96.4 | – | Form 10-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Amgen R&D Financing Liability Amortization ($M), annual FY2022–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/amgen-fin-commit-amort
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.